GO:0001525 angiogenesis: Blood Vessel Formation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001525 angiogenesis is the biological process by which new blood vessels emerge from the proliferation of pre-existing blood vessels.
• Angiogenesis is driven by a balance of pro-angiogenic factors such as VEGFA and anti-angiogenic factors such as thrombospondin-1.
• The process proceeds through endothelial activation, basement membrane degradation, sprouting, lumen formation, and stabilization by pericytes.
• Pathological angiogenesis underlies tumor growth, diabetic retinopathy, and inflammatory disease, making it a major therapeutic target.
• Oxidative stress and redox enzymes such as GPX1 and PPT1 modulate angiogenic signaling.
• CRISPR knockout, knock-in, and overexpression models enable causal testing of angiogenesis genes in endothelial and disease-relevant cells.
Description
Angiogenesis, annotated as GO:0001525, is the biological process in which new blood vessels arise from the proliferation of pre-existing blood vessels. It is distinct from vasculogenesis, which refers to de novo vessel formation from endothelial progenitors, and it is a fundamental mechanism for tissue growth, repair, and homeostasis. Folkman proposed that tumor growth is angiogenesis-dependent, establishing angiogenesis as a central target in cancer and other diseases. The process is tightly regulated by a balance of pro-angiogenic and anti-angiogenic signals, and its dysregulation contributes to tumor progression, diabetic retinopathy, and chronic inflammatory disorders. Because angiogenesis is a multi-step, multi-cell process, researchers study it using endothelial cell models, animal models, and genome-wide perturbation screens. Understanding the molecular players and regulatory logic of angiogenesis is therefore essential for developing therapies that either promote or inhibit vessel growth.
angiogenesis At A Glance
| GO ID | GO:0001525 |
|---|---|
| GO term | angiogenesis |
| Ontology | biological_process |
| Synonym | blood vessel formation from pre-existing blood vessels |
| Major function | Formation of new blood vessels from pre-existing vessels |
| Key regulators | VEGFA, VEGFR2, ANG1/ANG2, FGF2, Notch, ephrins |
| Cellular players | Endothelial cells, pericytes, smooth muscle cells, myeloid cells |
| Disease relevance | Cancer, diabetic retinopathy, inflammatory disease, ischemia |
What Is GO:0001525?
GO:0001525 angiogenesis is defined as blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels. In other words, it is the sprouting, splitting, or remodeling of existing vasculature rather than the initial assembly of vessels from progenitor cells. This process involves endothelial cell activation, migration, proliferation, and tube formation, and it is controlled by growth factors, receptors, and extracellular matrix interactions.
Why Is angiogenesis Important in Cell Biology?
Angiogenesis is essential for normal development, wound healing, and tissue regeneration, but it also drives pathological conditions such as tumor growth, diabetic retinopathy, and chronic inflammation. Because vessels supply oxygen and nutrients, blocking angiogenesis can starve tumors, while promoting angiogenesis can rescue ischemic tissues. The process is therefore a major therapeutic axis, with VEGF/VEGFR inhibitors and other anti-angiogenic agents used in the clinic.
• Supports embryonic development and organ growth by delivering oxygen and nutrients.
• Is required for wound healing and tissue repair after injury.
• Drives tumor growth and metastasis by supplying the tumor microenvironment.
• Contributes to diabetic retinopathy and other retinal vascular diseases.
• Is implicated in inflammatory and autoimmune diseases through vascular remodeling.
• Is a target for anti-angiogenic cancer therapy and VEGF/VEGFR inhibitors.
• Is modulated by oxidative stress and redox enzymes such as GPX1 and PPT1.
• Can be studied with endothelial cell sprouting, tube formation, and in vivo assays.
• Involves crosstalk with immune cells such as microglia in the retina.
• Provides a model for understanding cell migration, proliferation, and matrix remodeling.
What Happens During angiogenesis?
Endothelial activation and growth factor signaling
In simple terms: Endothelial cells receive growth signals that tell them to start forming new vessels.
Angiogenesis begins when pro-angiogenic factors such as VEGFA bind to receptors like VEGFR2 on endothelial cells, triggering intracellular signaling that promotes survival, proliferation, and migration. This activation is balanced by anti-angiogenic cues, and the net balance determines whether new vessels form. Hypoxia and oxidative stress can further modulate these signals.
Basement membrane degradation and sprouting
In simple terms: The vessel wall is loosened so endothelial cells can sprout outward.
Activated endothelial cells secrete proteases that degrade the basement membrane, allowing them to migrate into the surrounding matrix. Tip cells lead the sprout, while stalk cells proliferate and elongate behind them, a process coordinated by Notch and ephrin signaling. This sprouting phase is a hallmark of angiogenesis.
Lumen formation and tube assembly
In simple terms: The sprouting cells organize into hollow tubes that become new vessels.
Endothelial cells rearrange to form a lumen, establishing a functional vessel tube. This step requires coordinated cell polarity, junction formation, and interaction with the extracellular matrix. Lumen formation is essential for perfusion and is often assessed in tube formation assays.
Stabilization and pericyte recruitment
In simple terms: New vessels are stabilized by supporting cells so they do not leak or regress.
Once a new vessel forms, pericytes and smooth muscle cells are recruited to stabilize it, and basement membrane is deposited. Angiopoietin-Tie signaling and platelet-derived growth factor pathways contribute to this maturation step. In pathological angiogenesis, stabilization is often defective, leading to leaky vessels.
Regression and pruning
In simple terms: Vessels that are not needed are removed to maintain a healthy network.
In the absence of survival signals, new vessels can regress through endothelial cell apoptosis and pruning. This negative regulation is important for normal tissue homeostasis and is often lost in tumors. Anti-angiogenic therapies aim to tip the balance toward regression.
Key Genes Involved in GO:0001525 angiogenesis
The following genes and proteins are central to angiogenesis and are frequently studied in endothelial and disease models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VEGFA | Primary pro-angiogenic growth factor | Target of anti-angiogenic therapy; knockout and overexpression models |
| KDR (VEGFR2) | Main endothelial receptor for VEGFA | Key signaling node; point mutations and knockouts |
| FLT1 (VEGFR1) | Modulates VEGF signaling | Regulates angiogenesis; knockout models |
| ANGPT1 | Vessel stabilization via Tie2 | Pericyte recruitment; knock-in models |
| ANGPT2 | Vessel destabilization | Context-dependent regulator; knockout models |
| FGF2 | Pro-angiogenic factor | Synergizes with VEGF; overexpression models |
| NOTCH1 | Tip/stalk cell specification | Cell fate decisions; knockout models |
| DLL4 | Notch ligand in endothelium | Sprouting regulation; knockout models |
| EPHB4 | Ephrin receptor in endothelium | Vascular remodeling; knockout models |
| EFNB2 | Ephrin ligand in endothelium | Arteriovenous patterning; knockout models |
| HIF1A | Hypoxia-induced transcription factor | Drives VEGFA expression; knockout models |
| GPX1 | Redox enzyme modulating angiogenesis | Palmitoylation regulates activity; knockout models |
| PPT1 | Palmitoyl thioesterase | Target to inhibit angiogenesis; knockout models |
| TSP1 (THBS1) | Endogenous anti-angiogenic factor | Inhibits angiogenesis; overexpression models |
| PDGFB | Pericyte recruitment | Vessel stabilization; knockout models |
| TIE2 (TEK) | Angiopoietin receptor | Vessel maturation; point mutations |
| CDH5 (VE-cadherin) | Endothelial junction protein | Vessel integrity; knockout models |
How Is angiogenesis Regulated?
Angiogenesis is regulated by a balance of pro-angiogenic and anti-angiogenic signals, including VEGF/VEGFR, angiopoietin-Tie, Notch, and ephrin pathways. Hypoxia stabilizes HIF1A, which induces VEGFA and other pro-angiogenic genes. Oxidative stress and redox enzymes such as GPX1 and PPT1 further modulate angiogenic signaling through post-translational modifications. Anti-angiogenic factors such as thrombospondin-1 counterbalance these signals to prevent excessive vessel growth.
angiogenesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VEGFA | Cancer, diabetic retinopathy | Knockout and overexpression in endothelial cells |
| KDR (VEGFR2) | Cancer, vascular anomalies | Point mutation knock-in in endothelial cells |
| GPX1 | Oxidative stress-related angiogenesis | Knockout and palmitoylation-site knock-in |
| PPT1 | Angiogenesis inhibition | Knockout and overexpression models |
| HIF1A | Hypoxia-driven angiogenesis | Knockout in cancer cell lines |
Angiogenesis in cancer
Tumors require new blood vessels to grow beyond a small size, and angiogenesis is therefore a hallmark of cancer progression. VEGF/VEGFR signaling is a major driver, and anti-angiogenic therapies targeting this pathway are used in multiple cancers. However, resistance and alternative modes of vessel formation can limit efficacy, motivating research into additional targets.
Angiogenesis in diabetic retinopathy
Diabetic retinopathy is characterized by pathological retinal angiogenesis, which can lead to vision loss. Microglia and inflammatory signals contribute to retinal angiogenesis in this disease. Anti-VEGF therapies are used clinically, but understanding the cellular players remains important for new treatments.
Angiogenesis in inflammatory and ischemic disease
Chronic inflammation can promote angiogenesis, which in turn sustains inflammatory cell recruitment. In ischemic tissues, therapeutic angiogenesis aims to restore blood flow, but uncontrolled vessel growth can be harmful. Redox regulation by GPX1 and PPT1 has been implicated in modulating these responses.
From angiogenesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a gene required for endothelial sprouting? | CRISPR knockout in HUVECs or endothelial cells |
| Does a point mutation alter VEGFR2 signaling? | Point-mutation knock-in in endothelial cells |
| Does a gene promote angiogenesis when overexpressed? | Overexpression in endothelial cells or zebrafish |
| How does a gene affect vessel stabilization? | Knock-in of tagged protein in pericytes |
| What is the role of a gene in retinal angiogenesis? | Knockout in mouse retina models |
| Can a gene be targeted to inhibit tumor angiogenesis? | Xenograft models with CRISPR-edited cancer cells |
How to Study the angiogenesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Tube formation assay | Capillary-like network formation | In vitro angiogenesis screening |
| Sprouting assay | Endothelial sprout outgrowth | Gene function in sprouting |
| Retinal angiogenesis model | Vessel growth in retina | Diabetic retinopathy research |
| Tumor xenograft | Tumor vessel density | Anti-angiogenic therapy testing |
| RNA-seq | Gene expression changes | Pathway discovery |
| Proteomics | Protein abundance and modifications | Redox regulation studies |
| Live imaging | Dynamic vessel formation | Sprouting and stabilization |
Endothelial cell sprouting and tube formation assays
In vitro sprouting and tube formation assays measure the ability of endothelial cells to form capillary-like structures, a key step in angiogenesis. These assays are widely used to test the effect of gene knockouts or inhibitors.
In vivo angiogenesis models
Mouse retinal angiogenesis, Matrigel plug, and tumor xenograft models allow assessment of vessel growth in a physiological context. These models are essential for translating in vitro findings.
Transcriptomics and proteomics
RNA-seq and proteomics can identify gene expression changes during angiogenesis and reveal regulatory networks. These approaches help pinpoint candidate genes for functional studies.
Imaging and reporter systems
Live imaging of fluorescently labeled endothelial cells and reporter mice enables real-time visualization of sprouting and vessel stabilization. Imaging is often combined with genetic perturbation to study gene function.
How CRISPR Can Be Used to Study GO:0001525 angiogenesis
Knockout
CRISPR knockout of angiogenesis genes such as VEGFA or KDR in endothelial cells can reveal their requirement for sprouting and tube formation. Knockout models are also used in vivo to study retinal and tumor angiogenesis.
Point Mutation
Point-mutation knock-in can model activating or inactivating mutations in receptors like KDR or TEK, helping to dissect signaling mechanisms. Such models are valuable for studying vascular anomalies and drug resistance.
Knock-in
Knock-in of tagged proteins or reporters allows visualization and biochemical analysis of angiogenesis regulators in their native context. This approach is useful for tracking protein localization during sprouting.
Overexpression
Overexpression of pro-angiogenic factors such as VEGFA or FGF2 can drive excessive angiogenesis in cell and animal models. Overexpression models help test sufficiency and identify downstream effects.
How EDITGENE Supports angiogenesis Research
Researchers studying angiogenesis-related genes often need to determine whether a candidate gene is causally involved in vessel formation, and CRISPR-based models provide a direct way to test this. By combining knockout, point-mutation, knock-in, and overexpression strategies, it is possible to dissect the role of each gene in endothelial sprouting, stabilization, and disease-associated angiogenesis.
Contact EDITGENE today to design your custom CRISPR model for angiogenesis research.
Frequently Asked Questions About angiogenesis
What is angiogenesis GO:0001525?
GO:0001525 angiogenesis is the biological process of blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels.
What genes are involved in angiogenesis?
Key genes include VEGFA, KDR (VEGFR2), FLT1, ANGPT1, ANGPT2, FGF2, NOTCH1, DLL4, EPHB4, EFNB2, HIF1A, GPX1, PPT1, and THBS1.
How is angiogenesis regulated?
Angiogenesis is regulated by a balance of pro-angiogenic and anti-angiogenic signals, including VEGF/VEGFR, angiopoietin-Tie, Notch, and ephrin pathways, as well as hypoxia and oxidative stress.
What diseases are associated with angiogenesis?
Angiogenesis is associated with cancer, diabetic retinopathy, inflammatory diseases, and ischemic conditions.
How can I study angiogenesis in the lab?
Common methods include endothelial tube formation and sprouting assays, retinal angiogenesis models, tumor xenografts, RNA-seq, proteomics, and live imaging.
What is the difference between angiogenesis and vasculogenesis?
Angiogenesis refers to new vessels from pre-existing vessels, while vasculogenesis is de novo vessel formation from endothelial progenitors.
Which signaling pathway is most important in angiogenesis?
The VEGF/VEGFR pathway is the most prominent, but Notch, angiopoietin-Tie, and ephrin pathways are also critical.
Can CRISPR be used to study angiogenesis?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models are widely used to study angiogenesis genes in endothelial cells and animal models.
What is the role of oxidative stress in angiogenesis?
Oxidative stress can modulate angiogenesis, and redox enzymes such as GPX1 and PPT1 influence angiogenic signaling.
How do microglia affect retinal angiogenesis?
Microglia contribute to retinal angiogenesis and diabetic retinopathy through inflammatory and vascular interactions.
Conclusion
GO:0001525 angiogenesis is a central biological process that governs new blood vessel formation from pre-existing vessels, with profound implications for development, cancer, and vascular disease. Understanding its molecular players and regulatory logic is essential for therapeutic development. CRISPR-based models and functional screens provide powerful tools to dissect angiogenesis mechanisms and identify new targets.
References
- 1. Dudley AC et al.. 2023. Pathological angiogenesis: mechanisms and therapeutic strategies.. Angiogenesis 26(3):313-347 PMID: 37060495
- 2. Hu A et al.. 2024. Microglia in retinal angiogenesis and diabetic retinopathy.. Angiogenesis 27(3):311-331 PMID: 38564108
- 3. Dudley AC et al.. 2023. The modes of angiogenesis: an updated perspective.. Angiogenesis 26(4):477-480 PMID: 37640982
- 4. Lorenc P et al.. 2024. Physiological and tumor-associated angiogenesis: Key factors and therapy targeting VEGF/VEGFR pathway.. Biomed Pharmacother 180:117585 PMID: 39442237
- 5. Folkman J. 2006. Angiogenesis.. Annu Rev Med 57:1-18 PMID: 16409133
- 7. Ma Y et al.. 2024. Enhancing Gpx1 palmitoylation to inhibit angiogenesis by targeting PPT1.. Redox Biol 77:103376 PMID: 39423458
- 8. Huang YJ et al.. 2019. Oxidative stress-induced angiogenesis.. J Clin Neurosci 63:13-16 PMID: 30837109
